What is the recommended treatment for a Citrobacter freundii urinary tract infection (UTI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Citrobacter freundii UTI

For uncomplicated Citrobacter freundii UTI, use nitrofurantoin 100 mg PO every 6 hours for 5-7 days or fosfomycin 3 g PO single dose as first-line therapy, while for complicated UTI or severe infection, carbapenems (meropenem or imipenem) remain the most reliable empiric choice pending susceptibility results. 1, 2

Severity-Based Treatment Algorithm

Uncomplicated Lower UTI (Simple Cystitis)

  • Nitrofurantoin 100 mg PO every 6 hours for 5-7 days is the preferred first-line agent 2, 3
  • Fosfomycin 3 g PO single dose is an excellent alternative with high urinary concentrations 2, 3
  • Single-dose aminoglycoside can be considered if the organism is susceptible 4

Complicated UTI or Pyelonephritis

  • Carbapenems (imipenem or meropenem) are the most active agents against C. freundii and should be used for empiric therapy in severe infections 1
  • Cefepime is an alternative fourth-generation cephalosporin with good activity 1, 2
  • Piperacillin-tazobactam can be used for moderate infections when susceptibility is confirmed 2, 3

Critical Resistance Considerations

C. freundii possesses inducible AmpC β-lactamase, making it inherently resistant to most first-, second-, and third-generation cephalosporins, as well as anti-pseudomonal penicillins 1. This is a common pitfall—avoid using ceftriaxone, cefotaxime, ceftazidime, or ampicillin-sulbactam as they will likely fail.

Agents to AVOID:

  • First-, second-, and third-generation cephalosporins (high resistance rates) 1
  • Trimethoprim-sulfamethoxazole (increasing resistance) 2
  • Fluoroquinolones for empiric therapy (markedly decreased susceptibility over time, reserve for directed therapy only) 1, 2
  • Aztreonam (high resistance) 1

If Multidrug Resistance is Suspected

For complicated UTI with concern for carbapenem resistance or ESBL production:

  • Ceftazidime-avibactam 2.5 g IV q8h is recommended for carbapenem-resistant Enterobacterales 4
  • Meropenem-vaborbactam 4 g IV q8h or imipenem-cilastatin-relebactam 1.25 g IV q6h are newer β-lactam/β-lactamase inhibitor combinations 4
  • Plazomicin 15 mg/kg IV q12h (aminoglycoside) for complicated UTI due to resistant organisms 4

Duration of Therapy

  • Uncomplicated cystitis: 5-7 days (or single dose for fosfomycin) 2, 3
  • Complicated UTI/pyelonephritis: 7-14 days depending on clinical response 3, 5
  • Severe infections with bacteremia: 14-21 days 5

Key Clinical Pearls

Always obtain urine culture and susceptibility testing before initiating therapy for complicated UTI, as resistance patterns are unpredictable 3, 5. De-escalate therapy once susceptibilities return to preserve carbapenem activity.

Consider prolonged infusion of β-lactams (administered over 3-4 hours) when treating organisms with elevated MICs to optimize pharmacodynamic targets 4.

Infectious disease consultation is strongly recommended for management of multidrug-resistant C. freundii infections 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.